Market Overview

UPDATE: Morgan Stanley Reiterates On CIGNA As 4Q Issues May Linger

Related CI
Virginia Cancer Institute and Cigna Collaborate to Improve Care for People Undergoing Cancer Treatment
CIGNA CEO Explains Why The Anthem-CIGNA Deal Won't Face Antitrust Issues
Big Health Insurers Consolidate...Should You Buy? (Seeking Alpha)

In a report published Friday, Morgan Stanley analyst Andrew Schenker reiterated an Overweight rating on CIGNA (NYSE: CI), but lowered the price target from $100.00 to $93.00.

In the report, Morgan Stanley noted, “Issues CI experienced in 4Q may spill over into 2014 results. However, >$1.5B in deployable cash in FY14 and improvements in 2H14 should yield mid single-digit EPS growth. Our adjusted EPS of $7.16 reflects 6% Y/Y growth off a lower 2013 platform.”

CIGNA closed on Friday at $76.14.

Latest Ratings for CI

Jul 2015BarclaysMaintainsEqual-weight
Jul 2015Sterne AgeeUpgradesNeutralBuy
Jul 2015SusquehannaMaintainsPositive

View More Analyst Ratings for CI
View the Latest Analyst Ratings

Posted-In: Andrew Schenker Morgan StanleyAnalyst Color Price Target Analyst Ratings


Related Articles (CI)

Get Benzinga's Newsletters